Access the full text.
Sign up today, get DeepDyve free for 14 days.
Daniel Guillaume, P. Bertrand, D. Dea, J. Davignon, J. Poirier (1996)
Apolipoprotein E and Low‐Density Lipoprotein Binding and Internalization in Primary Cultures of Rat Astrocytes: Isoform‐Specific AlterationsJournal of Neurochemistry, 66
W. Mcdonald, D. Miller, D. Barnes (1992)
The pathological evolution of multiple sclerosisNeuropathology and Applied Neurobiology, 18
K. Johnson, B. Brooks, Jeffrey Cohen, C. Ford, Jill Goldstein, R. Lisak, L. Myers, H. Panitch, J. Rose, R. Schiffer, T. Vollmer, L. Weiner, J. Wolinsky (1995)
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 45
L. Barcellos, G. Thomson, M. Carrington, J. Schafer, A. Begovich, P. Lin, Xu Xh, Min Bq, D. Marti, W. Klitz (1997)
Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis. Evidence of a new susceptibility locus in Caucasian and Chinese patients.JAMA, 278
N. Rifai, R. Christenson, B. Gelman, L. Silverman (1987)
Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination.Clinical chemistry, 33 7
M. Ignatius, P. Gebicke-Harter, J. Skene, J. Schilling, K. Weisgraber, R. Mahley, E. Shooter (1986)
Expression of apolipoprotein E during nerve degeneration and regeneration.Proceedings of the National Academy of Sciences of the United States of America, 83 4
S. Barger, A. Harmon (1997)
Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein ENature, 388
B. Nathan, S. Bellosta, D. Sanan, K. Weisgraber, R. Mahley, R. Pitas (1994)
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.Science, 264 5160
C. Poser, D. Paty, L. Scheinberg, W. Mcdonald, F. Davis, G. Ebers, K. Johnson, W. Sibley, D. Silberberg, W. Tourtellotte (1983)
New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 13
L. Minthon, C. Hesse, M. Sjögren, E. Englund, L. Gustafson, K. Blennow (1997)
The apolipoprotein E ϵ4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of diseaseNeuroscience Letters, 226
S. Bellosta, B. Nathan, M. Orth, L. Dong, R. Mahley, R. Pitas (1995)
Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth (*)The Journal of Biological Chemistry, 270
P. Puttfarcken, A. Manelli, M. Falduto, G. Getz, M. LaDu (1997)
Effect of Apolipoprotein E on Neurite Outgrowth and β‐Amyloid‐Induced Toxicity in Developing Rat Primary Hippocampal CulturesJournal of Neurochemistry, 68
B. Moulard, A. Sefiani, Aboubakr Laamri, A. Malafosse, W. Camu (1996)
Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosisJournal of the Neurological Sciences, 139
S. Messmer-Joudrier, Y. Sagot, L. Mattenberger, R. James, A. Kato (1996)
Injury‐induced Synthesis and Release of Apolipoprotein E and Clusterin from Rat Neural CellsEuropean Journal of Neuroscience, 8
B. Tardiff, M. Newman, A. Saunders, W. Strittmatter, J. Blumenthal, William Mph, Narda Crna, R. Davis, A. Roses, J. Reves (1997)
Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center.The Annals of thoracic surgery, 64 3
B. Gelman, N. Rifai, J. Goodrum, T. Bouldin, M. Krigman (1987)
Apolipoprotein E is Released by Rat Sciatic Nerve During Segmental Demyelination and RemyelinationJournal of Neuropathology and Experimental Neurology, 46
T. Treves, N. Bornstein, J. Chapman, S. Klimovitzki, R. Verchovsky, A. Asherov, I. Veshchev, A. Korczyn (1996)
APOE-ε4 in Patients with Alzheimer Disease and Vascular DementiaAlzheimer Disease & Associated Disorders, 10
Daniel Laskowitz, S. Goel, E. Bennett, William Matthew (1997)
Apolipoprotein E suppresses glial cell secretion of TNFαJournal of Neuroimmunology, 76
R. Bo, G. Comi, N. Bresolin, E. Castelli, E. Conti, A. Degiuli, C. Ausenda, G. Scarlato (1997)
The apolipoprotein E ϵ4 allele causes a faster decline of cognitive performances in Down's syndrome subjectsJournal of the Neurological Sciences, 145
W. Strittmatter, A. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G. Salvesen, A. Roses (1993)
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.Proceedings of the National Academy of Sciences of the United States of America, 90
J. Kurtzke (1983)
Rating neurologic impairment in multiple sclerosisNeurology, 33
G. Stoll, H. Mueller, B. Trapp, J. Griffin (1989)
Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerveGlia, 2
Catherine Gutman, W. Strittmatter, K. Weisgraber, W. Matthew (1997)
Apolipoprotein E Binds to and Potentiates the Biological Activity of Ciliary Neurotrophic FactorThe Journal of Neuroscience, 17
B. Ferguson, M. Matyszak, M. Esiri, V. Perry (1997)
Axonal damage in acute multiple sclerosis lesions.Brain : a journal of neurology, 120 ( Pt 3)
ruce, T. D., Rapp, Ohn, Eterson, ichard, R. M, Ansohoff, Udick, Verre, Örk (1998)
AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS
K. Johnson, B. Brooks, Jeffrey Cohen, C. Ford, J. Goldstein, R. Lisak, L. Myers, H. Panitch, J. Rose, R. Schiffer, T. Vollmer, L. Weiner, J. Wolinsky (1995)
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.Neurology, 45 7
T. Arendt, C. Schindler, M. Brückner, K. Eschrich, V. Bigl, D. Zedlick, L. Marcova (1997)
Plastic Neuronal Remodeling Is Impaired in Patients with Alzheimer’s Disease Carrying Apolipoprotein ε4 AlleleThe Journal of Neuroscience, 17
J. Poirier, A. Baccichet, D. Dea, S. Gauthier (1993)
Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult ratsNeuroscience, 55
(1997)
Copolymer 1 in relapsing-remitting multiple sclerosis: a multi-center trial
J. Chapman, J. Estupiñán, Alexander Asherou, L. Goldfarb (1996)
A simple and efficient method for apolipoprotein E genotype determinationNeurology, 46
D. Rubinsztein, Charlotte Hanlon, R. Irving, S. Goodburn, D. Evans, Helen Keller-Wood, J. Xuereb, O. Bandmann, A. Harding (1994)
Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease.Molecular and cellular probes, 8 6
BackgroundApolipoprotein E expression is increased in regenerating neural tissue and the APOEε4 allele is associated with impaired neuronal repair. Since repair is essential for the restoration of central nervous system function following multiple sclerosis (MS) relapses, APOEgenotype may influence clinical progression of the disease.ObjectiveTo examine the association of the APOEgenotype with disease susceptibility and progression in MS.Patients and MethodsAPOEgenotyping was determined by polymerase chain reaction and restriction enzyme digestion in 47 patients with MS who had been followed up every 3 months for 2 years as part of an open-label clinical trial with glatiramer acetate. The Expanded Disability Status Scale (EDSS) was used to assess clinical progression.ResultsNine patients were heterozygous and 1 patient was homozygous for the APOEε4 allele, for a frequency of 12% (11/94), which is similar to that of the general Israeli population. The APOEε4 carriers had a mean ± SE EDSS score of 3.10 ± 0.45 at entry, which was not significantly different from the remaining 37 patients (2.62 ± 0.25). During the observation period, the EDSS score of the APOEε4 carriers deteriorated to 4.00 ± 0.63 while the other patients remained stable with an EDSS score of 2.74 ± 0.31. The interaction of genotype with disability over time was significant (P= .02 by repeated-measures analysis of variance). There were no differences in the number of relapses occurring in the 2 groups.ConclusionsThese preliminary observations suggest that APOEgenotype may influence disease progression in MS. The APOEε4 allele was not associated with an increased risk of MS or relapses.APOLIPOPROTEIN E (apoE) is involved in the transport of lipids in the serum. Several lines of evidence suggest that it is also involved in the regeneration of axons and myelin following lesions of central and peripheral nervous tissue, including a significant increase of apoE in regenerating peripheral nerveand central nervous system tissue.In in vitro studies, apoE acts as a nerve growth factoror cofactor.In humans, there are 3 common alleles of APOE, the gene coding for apoE, ε2, ε3, and ε4. The APOEε4 allele has been consistently associated with an increased risk of Alzheimer disease.The proposed mechanisms for this association include inadequate repair,which may be relevant to other neurologic illnesses since repair determines to a large extent the development of disability. Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that is characterized mainly by exacerbations followed by remissions. Although some patients with MS have a relentlessly progressive course of the disease from onset, the majority recover from early relapses, some of whom remain stable for many years, while others develop progressive disability. Since repair is essential for the restoration of central nervous system function following MS relapses, APOEgenotype may influence clinical progression of the disease. In the present study we examined the association of APOEgenotype with disease susceptibility and progression in MS.PATIENTS AND METHODSThe study group included 47 patients with MS who had a clinically definiterelapsing-remitting course. They were enrolled by informed consent in an open-label trial with copolymer 1 (glatiramer acetate [Copaxone], Teva Pharmaceuticals, Kfar Saba, Israel) from 1990 to 1997. The clinical inclusion and exclusion criteria used in this study are detailed elsewhere,and in principle included patients with mild to moderate relapsing-remitting disease. Since interferon treatment was not available at that time, most, if not all, eligible patients were included without a selection bias. Patients were examined every 3 months according to a protocol that included a detailed neurologic examination and assessment of the Kurtzke functional systems Expanded Disability Status Scale (EDSS).During and following all exacerbations, a full examination including the EDSS was performed. For all missing data, the last observation was carried forward in the statistical analysis. Progression was defined as a deterioration in the EDSS score maintained over 2 consecutive examinations 3 months apart.DNA was isolated from routine blood samples obtained as approved by the institutional review board. Identification of APOEε4 alleles was carried out as previously described.The genotyping was performed at the end of the follow-up period and the physicians were blinded to these data when evaluating the patients.For variables with a single measurement per patient, the groups with or without APOEε4 alleles were compared by means of independent ttests or the Fisher exact test. For comparison of EDSS measures over time, an analysis of variance (ANOVA) with repeated measures was used. Significance was set at P<.05, and data are reported as mean ± SE.RESULTSWe found that 9 patients were heterozygous and 1 patient was homozygous for the APOEε4 allele. The ε4 allele frequency of 12% (11/94) in these patients with MS was similar to that of the general Israeli population.In the subsequent analysis, the homozygous patient was included in the APOEε4 carrier group. Excluding the 1 patient homozygous for the APOEε4 allele does not alter significantly any of the subsequent results.Table 1summarizes the characteristics of patients with and without APOEε4 alleles at entry into the study. Mean age and male-to-female ratio were similar in both groups. The APOEε4 carriers had a shorter duration of illness at entry (48 ± 12 months vs 57 ± 10 months), a similar exacerbation rate over the previous 2 years (1.05 ± 0.05 per year vs 1.12 ± 0.06), and a higher EDSS score (3.10 ± 0.45 vs 2.62 ± 0.25). None of these differences, however, was statistically significant (P>.35 for all comparisons).Characteristics of Patients With Multiple Sclerosis at Study Entry*CharacteristicAPOEε4 (n = 10)Non–APOEε4 (n = 37)Age, y34.0 ± 1.436.0 ± 2.3M/F ratio1:1.51:1.4Duration of disease, mo48 ± 1257 ± 10EDSS score at entry (range)3.10 ± 0.45 (1.5-6.0)2.62 ± 0.25 (0-6.0)Exacerbation rate, per year1.05 ± 0.051.12 ± 0.06*Data are given as mean ± SE unless otherwise noted. EDSS indicates Expanded Disability Status Scale. The variables of APOEε4 carriers (APOEε4) and patients without APOEε4 (non-ε4) were collected at study entry as described in the "Patients and Methods" section. The exacerbation rate was calculated for the 2 years prior to the study period. No statistically significant differences were observed between the groups in any of these variables.Figure 1summarizes the mean EDSS scores of both groups during the 2 years of observation. During the first year, a single (non–APOEε4 carrier) patient was lost to follow-up. Only this non–APOEε4 carrier was not observed for the 2 full years. During this 2-year observation period, the APOEε4 carriers' disease course deteriorated to a mean EDSS score of 4.00 ± 0.63 while the other patients remained stable with a score of 2.74 ± 0.31. The interaction of genotype with disability over time was significant (P= .02 by repeated-measures ANOVA). Analysis of the cases by the criteria of sustained change in EDSS revealed that 7 (70%) of the 10 APOEε4 carriers compared with 13 (35%) of the 37 non–APOEε4 carriers had progressed in their disability (P= .03, Fisher exact test). Since some patients were under observation for longer periods, we performed a similar analysis over 4 years. Only 4 APOEε4 carriers and 13 noncarriers were observed to the end of this period. However, if the missing data are completed by carrying the last observation forward, the trend to progression continued in the APOEε4 carriers (EDSS score = 4.30 ± 0.64) whereas the non–APOEε4 group remained relatively stable (EDSS score = 2.91 ± 0.33).Mean (SE) Expanded Disability Status Scale (EDSS) scores as a function of observation time in patients with multiple sclerosis carrying APOEε4 alleles and noncarriers with multiple sclerosis. Data on APOEε4 carriers included 10 patients at onset, of whom 2 were withdrawn during the second year of observation and the value of their last observation was carried forward in the data analyses. There were 37 patients without APOEε4 alleles, of whom 4 were withdrawn during the observation period and whose last observation was carried forward in the analysis. A repeated-measures analysis of variance revealed significant interaction of genotype with change in disability over time (P= .02).During the first 2 years of follow-up, the non–APOEε4 carriers had 12 exacerbations (2 of which were recurrent), which was proportionally similar to the 3 exacerbations observed in carriers. Mean EDSS scores before, at the peak, and at the resolution of the exacerbation, respectively, were 3.67 ± 1.30, 4.67 ± 1.30, and 4.50 ± 1.26 in the ε4 group compared with 2.00 ± 0.54, 3.37 ± 0.44, and 2.04 ± 0.52 in the non-ε4 group. Analysis by repeated-measures ANOVA of the EDSS scores before and at the peak of the exacerbation did not reveal any significant difference between the groups. However, similar analysis of the EDSS scores during the peak of the exacerbation and at resolution, revealed a borderline significant interaction of group with the repeated measure (P= .049, 1 tailed). Thus, although the groups did not differ in the severity of the relapses, there was some indication of impaired recovery in the APOEε4 carriers.COMMENTOur results implicate the APOEε4 allele as a factor determining the accumulation of disability in MS, although it is not associated with a higher risk of developing the disease itself. The latter finding is in accord with previous studies, which did not find this allele to be a risk factor for the development of MS.To our knowledge, the present study is the first to link the APOEε4 allele and progression of disability in MS. Although the assay used in the present study did not identify ε2 alleles, the expected number of these alleles is less than 5% and there is no evidence that they influence neuronal repair.The effect of the APOEε4 allele was statistically significant despite the groups being relatively small. This effect was consistently found regardless of whether data were analyzed by comparing group means or by a nonparametric analysis of disease progression. The slightly shorter duration of illness with higher EDSS scores at entry in the APOEε4 group are also compatible with a worse prognosis in this group. To offset the effect of higher EDSS scores of the APOEε4 group at entry into the study we analyzed the results omitting the APOEε4 patient with the highest EDSS score at entry (6.0) and the 6 non-ε4 patients with the lowest EDSS score at entry (1.0). This resulted in slightly higher entry mean EDSS scores in the non-ε4 group (2.94 ± 0.26 vs 2.78 ± 0.34); nevertheless, the ε4 patients were still found to progress significantly more over time (P= .02 by repeated-measures ANOVA). If only patients with EDSS scores between 1.5 and 5.5 are included in an alternate analysis, the resulting mean EDSS scores at entry were 2.78 ± 0.34 in the ε4 group (n = 9) and 2.61 ± 0.20 in the non-ε4 group (n = 28), and the ε4 carriers were still found to progress significantly more over time (P= .04). In addition, what data there are from the few relapses are compatible with impairment in recovery in the APOEε4 carriers. It is important to note that the data set for the smaller group of APOEε4 carriers was complete for the main observation period of 2 years. Interestingly, the single homozygous patient did not experience disease progression during this period, and had she been excluded from the analysis, the statistical significance of the results would have been enhanced.Following acute MS exacerbations, recovery results from several factors, primarily resolution of edema. Over the long term, however, accumulated disability may result from other factors such as residual extensive demyelination after exacerbations and primary axonal damage. Further studies are needed to investigate the correlation of APOEwith specific mechanisms involved in MS progression. The available data indicate that the association between APOEand disability in MS could be due to many factors, including modulation of immune processes and preservation of neuronal function and repair capacity following demyelination. Although there is some evidence for a differential immunomodulatory role for the different apoE types, there is far more evidence supporting their differing effects on repair, especially that associated with lipid metabolism.Specifically linking apoE and demyelination are the observations that oligodendroglia are most involved in producing apoE in the injured optic nerve,that apoE is released in segmental demyelination of the sciatic nerve,and that cerebrospinal fluid levels of apoE correlate with MS exacerbations.A significant effect of APOEgenotype on functional disability in MS is compatible with its effect in other neurodegenerative diseases. Clinical evidence links the APOEε4 allele with earlier age at onset of frontotemporal dementia,faster decline of cognitive performance in persons with Down syndrome,worse prognosis of motor neuron disease,and cognitive decline following cardiac surgery.Molecular evidence indicates that apoE ε4 is associated with impaired regeneration,is internalized into neurons less than apoE ε3,and is associated with reduced neurite outgrowth in cultured dorsal root gangliaand neuroblastoma cells.These properties are of special relevance in view of the axonal degeneration reported in MS.Interestingly, one of the proteins that accumulates during axonal damage in MS is the β-amyloid precursor protein,which is known to interact with apoE in Alzheimer disease. The factors that influence the extent of axonal injury in MS may include neurotrophic factors such as apoE.The extent of axonal injury may, in turn, determine the progression of disability in the disease.The immunomodulatory effects of apoE include suppression of tumor necrosis factor α secretion by glial cellsand genotype-specific modulation of microglial activation.In the present study, however, there was no evidence that APOEε4 is associated with a higher incidence of MS, more frequent relapses, or severity of relapses. These findings do not support a major role of APOEgenotype in the regulation of the inflammatory immune process in MS. It is interesting to note that the progression of disability in the APOEε4 carriers was not associated with documented exacerbations but rather to insidious deterioration. The APOEε4 allele may therefore be associated with a propensity to transform the course of MS from a relapsing-remitting to a secondary progressive form.Evidently, the observation period in the present study was relatively short and the data must be viewed in the perspective of a chronic disease lasting for decades. We are currently examining the hypothesis that the proportion of APOEε4 carriers is higher in progressive forms of MS than in patients with a long-standing benign course. All the patients in the present study were white and were receiving copolymer 1 (glatiramer acetate), which raises the possibility of an interaction between APOEand these factors. It is theoretically possible that the results are not due to a direct effect of APOEstatus on the natural history of the disease but rather are an interaction with the copolymer 1 treatment. However, we consider this possibility unlikely since the effects of copolymer 1 on disability over 2 years in the largest published study were marginal.Although of some interest, a comparative study on untreated patients followed up for long periods is both impractical and unethical.The results of this study are based on a relatively small number of patients over a relatively short period, and should be considered preliminary. If confirmed, there are several potential implications for the effect of APOEgenotype on disease progression in MS. It may be useful as a prognostic marker in counseling patients and as a variable in the analysis and comparison of clinical studies. It may explain some of the variance in disease progression between different clinical studies. The data are compatible with an effect of APOEgenotype on neuronal protection or repair, thus supporting a possible role for APOEgenotypes in central nervous system disease.MJIgnatiusPJGebicke-HarterJHSkeneExpression of apolipoprotein E during nerve degeneration and regeneration.Proc Natl Acad Sci U S A.1986;83:1125-1129.SMessmer-JoudrierYSagotLMattenbergerRWJamesACKatoInjury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells.Eur J Neurosci.1996;8:2652-2661.PSPuttfarckenAMManelliMTFaldutoGSGetzMJLaDuEffect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures.J Neurochem.1997;68:760-769.CRGutmanWJStrittmatterKHWeisgraberWDMatthewApolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor.J Neurosci.1997;17:6114-6121.WJStrittmatterAMSaundersDSchmechelApolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.Proc Natl Acad Sci U S A.1993;90:1977-1981.TATrevesNMBornsteinJChapmanAPOE-ε4 in patients with Alzheimer disease and vascular dementia.Alzheimer Dis Assoc Disord.1996;10:189-191.TArendtCSchindlerMKBrucknerPlastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein ε4 allele.J Neurosci.1997;17:516-529.CMPoserDWPatyLScheinbergNew diagnostic criteria for multiple sclerosis: guidelines for research protocols.Ann Neurol.1983;13:227-231.ZMeinerEKottDSchechterCopolymer 1 in relapsing-remitting multiple sclerosis: a multi-center trial.In: Abramsky O, Ovadia H, eds. Frontiers in Multiple Sclerosis: Clinical Research and Therapy.London, England: Martin Dunitz; 1997:213-221.JFKurtzkeRating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS).Neurology.1983;33:1444-1452.JChapmanJEstupinanAAsherovLGGoldfarbA simple and efficient method for apolipoprotein E genotype determination.Neurology.1996;46:1484-1485.LFBarcellosGThomsonMCarringtonChromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis: evidence of a new susceptibility locus in Caucasian and Chinese patients.JAMA.1997;278:1256-1261.DCRubinszteinCSHanlonRMIrvingApo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease.Mol Cell Probes.1994;8:519-525.JPoirierABaccichetDDeaSGauthierCholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats.Neuroscience.1993;55:81-90.GStollHWMeullerBDTrappJWGriffinOligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve.Glia.1989;2:170-176.BBGelmanNRifaiJFGoodrumTWBouldinMRKrigmanApolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination.J Neuropathol Exp Neurol.1987;46:644-652.NRifaiRHChristensonBBGelmanLMSilvermanChanges in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination.Clin Chem.1987;33:1155-1157.LMinthonCHesseMSjogrenEEnglundLGustafsonKBlennowThe apolipoprotein E ε4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease.Neurosci Lett.1997;226:65-67.RDel BoGPComiNBresolinThe apolipoprotein E ε4 allele causes a faster decline of cognitive performances in Down's syndrome subjects.J Neurol Sci.1997;145:87-91.BMoulardASefianiALaamriAMalafosseWCamuApolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis.J Neurol Sci.1996;139(suppl):34-37.BETardiffMFNewmanAMSaundersPreliminary report of a genetic basis for cognitive decline after cardiac operations: The Neurologic Outcome Research Group of the Duke Heart Center.Ann Thorac Surg.1997;64:715-720.DGuillaumePBertrandDDeaJDavignonJPoirierApolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations.J Neurochem.1996;66:2410-2418.BPNathanSBellostaDASananKHWeisgraberRWMahleyREPitasDifferential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.Science.1994;264:850-852.SBellostaBPNathanMOrthLMDongRWMahleyREPitasStable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth.J Biol Chem.1995;270:27063-27071.WIMcDonaldDHMillerDBarnesThe pathological evolution of multiple sclerosis.Neuropathol Appl Neurobiol.1992;18:319-334.BDTrappJPetersonRMRansohoffRRudickSMorkLBoAxonal transection in the lesions of multiple sclerosis.N Engl J Med.1998;338:278-285.BFergusonMKMatyszakMMEsiriVHPerryAxonal damage in acute multiple sclerosis lesions.Brain.1997;120:393-399.DTLaskowitzSGoelERBennettWDMatthewApolipoprotein E suppresses glial cell secretion of TNF alpha.J Neuroimmunol.1997;76:70-74.SWBargerADHarmonMicroglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E.Nature.1997;388:878-881.KPJohnsonBRBrooksJACohenCopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group.Neurology.1995;45:1268-1276.Accepted for publication April 16, 1999.This study was supported by the Sieratzki Chair of Neurology, Tel Aviv University, Tel Aviv, Israel; the Miriam Turjanski de Gold and Dr Roberto Gold Fund for Neurological Research, Buenos Aires, Argentina; and the Streifler Foundation, Tel Aviv.This study was presented in part at the annual meeting of the American Academy of Neurology, Minneapolis, Minn, April 29, 1998.Reprints: Amos D. Korczyn, MD, MSc, Sieratzki Chair of Neurology, Tel Aviv University, Ramat Aviv 69978, Israel (e-mail: neuro13@ccsg.tau.ac.il).
JAMA Neurology – American Medical Association
Published: Dec 1, 1999
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.